KalVista Pharmaceuticals, Inc. Company profile
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). Plasma kallikrein is a serine protease enzyme, which is an early mediator of inflammation and edema. The body modulates the inflammatory effects of plasma kallikrein through a circulating inhibitor protein called C1-esterase inhibitor (C1-INH). The Company is primary focused on the development of the oral plasma kallikrein inhibitors for HAE. It has two drug program candidates in clinical trials. The Company’s DME program is focused on the development of an intravitreally administered small molecule plasma kallikrein inhibitor, KVD001, which completed a Phase II trial.
Financial summary
BRIEF: For the nine months ended 31 January 2022, Kalvista Pharmaceuticals Inc revenues was not reported. Net loss increased 86% to $58.2M. Higher net loss reflects Research and development increase of 73% to $51M (expense), General and administrative increase of 80% to $18.8M (expense), foriegn exchange gain/loss decrease from $715K (income) to $529K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.75 to -$2.38.
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)